211 related articles for article (PubMed ID: 21464158)
1. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
Zurita AJ; Jonasch E; Wang X; Khajavi M; Yan S; Du DZ; Xu L; Herynk MH; McKee KS; Tran HT; Logothetis CJ; Tannir NM; Heymach JV
Ann Oncol; 2012 Jan; 23(1):46-52. PubMed ID: 21464158
[TBL] [Abstract][Full Text] [Related]
2. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
[TBL] [Abstract][Full Text] [Related]
4. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
Rini B; Szczylik C; Tannir NM; Koralewski P; Tomczak P; Deptala A; Dirix LY; Fishman M; Ramlau R; Ravaud A; Rogowski W; Kracht K; Sun YN; Bass MB; Puhlmann M; Escudier B
Cancer; 2012 Dec; 118(24):6152-61. PubMed ID: 22692704
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
[TBL] [Abstract][Full Text] [Related]
7. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
Heng DY; Mackenzie MJ; Vaishampayan UN; Bjarnason GA; Knox JJ; Tan MH; Wood L; Wang Y; Kollmannsberger C; North S; Donskov F; Rini BI; Choueiri TK
Ann Oncol; 2012 Jun; 23(6):1549-55. PubMed ID: 22056973
[TBL] [Abstract][Full Text] [Related]
8. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
[TBL] [Abstract][Full Text] [Related]
9. Targeting renal cell carcinoma.
Motzer RJ; Molina AM
J Clin Oncol; 2009 Jul; 27(20):3274-6. PubMed ID: 19451422
[No Abstract] [Full Text] [Related]
10. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Leung HW; Chan AL
Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
12. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.
Jonasch E; Corn P; Pagliaro LC; Warneke CL; Johnson MM; Tamboli P; Ng C; Aparicio A; Ashe RG; Wright JJ; Tannir NM
Cancer; 2010 Jan; 116(1):57-65. PubMed ID: 19862815
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
[TBL] [Abstract][Full Text] [Related]
14. Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.
Zurita AJ; Gagnon RC; Liu Y; Tran HT; Figlin RA; Hutson TE; D'Amelio AM; Sternberg CN; Pandite LN; Heymach JV
Br J Cancer; 2017 Aug; 117(4):478-484. PubMed ID: 28683470
[TBL] [Abstract][Full Text] [Related]
15. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
Grünwald V; Seidel C; Fenner M; Ganser A; Busch J; Weikert S
Br J Cancer; 2011 Nov; 105(11):1635-9. PubMed ID: 22033275
[TBL] [Abstract][Full Text] [Related]
16. Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
Furuya N; Kamai T; Shirataki H; Yanai Y; Fukuda T; Mizuno T; Nakamura F; Kambara T; Nakanishi K; Abe H; Yoshida K
Cancer Immunol Immunother; 2011 Jun; 60(6):793-808. PubMed ID: 21350947
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in renal cell carcinoma: what next?
Bukowski RM
Curr Oncol Rep; 2011 Apr; 13(2):87-9. PubMed ID: 21271363
[No Abstract] [Full Text] [Related]
18. Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma.
Msaouel P; Zurita AJ; Huang S; Jonasch E; Tannir NM
Oncotarget; 2017 Jun; 8(26):42149-42158. PubMed ID: 28178674
[TBL] [Abstract][Full Text] [Related]
19. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival.
Montero AJ; Diaz-Montero CM; Millikan RE; Liu J; Do KA; Hodges S; Jonasch E; McIntyre BW; Hwu P; Tannir N
Ann Oncol; 2009 Oct; 20(10):1682-7. PubMed ID: 19541791
[TBL] [Abstract][Full Text] [Related]
20. VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.
Liu F; Chen X; Peng E; Guan W; Li Y; Hu Z; Ye Z; Zhuang Q
J Huazhong Univ Sci Technolog Med Sci; 2011 Dec; 31(6):799-806. PubMed ID: 22173502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]